When entering the Title of your abstract, keep in mind that the abstract is limited to a total of 2,140 characters (not including spaces), INCLUDING the abstract title.

Author information does not count towards the character limit.

The authors included should be those who contribute significantly to the intellectual content of the abstract (maximum 50 authors). When adding authors to your abstract, the Full Name, Affiliation, Email Address, and professional specialty of each author must be included. You will be able to use the ISHLT database search tool on the submission site to search and add your authors. Authors will be listed in the author block in the order they are added but can be rearranged after adding.

The Submitting Author is responsible for notifying all named co-authors that they will be listed as a co-author on a submitted abstract.

The Presenting Author will be the only author to receive notification of acceptance/rejection of a submitted abstract; therefore, it is the Presenting Author's responsibility to notify all co-authors regarding the outcome of an abstract submission. If the abstract is accepted for presentation at the ISHLT2023 Annual Meeting, the Presenting Author must register to attend the meeting in person. If a change in Presenting Author must be made after the submission deadline, the Presenting Author will be given the opportunity to do so in January 2023.

Your abstract may be submitted into only one category. Submission of the same abstract into multiple categories is not permitted. Submission of one study as several different abstracts is also not permitted. If the abstracts in question are not different enough to be considered separate studies, or if the same abstract is submitted into multiple categories, all versions may be rejected.

Abstract Submission Categories are separated into four Core Therapies:

• ►  HEART (Advanced Heart Failure and Transplantation)
• ►  LUNG (Advanced Lung Failure and Transplantation)
• ►  MCS (Mechanical Circulatory Support)
• ►  PVD (Pulmonary Vascular Disease (PAH and CTEPH)

ABSTRACT SUBMISSION CATEGORIES:

	Advanced Heart Failure and Transplantation
■  HEART-Basic Science-Immunology, Inflammation ■  HEART-Basic Science-Models of Organ Preservation, Perfusion and Graft Injury ■  HEART-Basic Science-Translational Research/Novel Desensitization Strategies (i.e., CARS-T) ■  HEART-Basic Science-Translational Research/Other ■  HEART-Basic Science-Xenotransplantation/Regenerative Medicine/Artificial Organs ■  HEART-Cardiac Allograft Vasculopathy ■  HEART-Cardiogenic Shock (Pharmacologic Therapies, Recognition, Prognostication) ■  HEART-Clinical Ex-Vivo Perfusion and Preservation/Normothermic Regional Perfusion ■  HEART-Complications Other ■  HEART-Congenital Heart Disease Management ■  HEART-COVID 19 Donor Issues ■  HEART-COVID 19 Recipient Issues ■  HEART-Critical Care Medicine/Peri-operative/Intra-operative Management ■  HEART-Diagnostics and Imaging ■  HEART-Donor Management (including DCD and DBD) ■  HEART-Establishing New Heart Transplant Programs ■  HEART-Health Equity, Economics, Ethics, Public Policy ■  HEART-Immunology, Inflammation (Clinical) ■  HEART-Infectious Diseases - Diagnostics and Complications ■  HEART-Infectious Diseases - Management and Therapeutics ■  HEART-Multidisciplinary Team Care Delivery ■  HEART-Multidisciplinary Team Compliance/Adherence/Psychosocial Aspects ■  HEART-Multidisciplinary Team Palliative Care/Self Care/Symptom Management ■  HEART-Multi-Organ Transplant ■  HEART-Organ Allocation and Utilization ■  HEART-Outcomes (Effectiveness) ■  HEART-Outcomes (Other) ■  HEART-Outcomes (Risk Prediction/Modelling) ■  Outcomes (Safety) ■  HEART-Pathology ■  HEART-Patient Management/Patient Care Pathways ■  HEART-Patient Selection for Advanced Therapies/Rehabilitation/Frailty ■  HEART-Pediatrics-Basic Science/Translational Research ■  HEART-Pediatrics-Complications ■  HEART-Pediatrics-COVID-19 ■  HEART-Pediatrics-Heart Failure ■  HEART-Pediatrics-Other ■  HEART-Pediatrics-Outcomes ■  HEART-Pediatrics-Patient Selection, Organ Allocation, Donor Management ■  HEART-Pharmacology, Therapeutics, Immunosuppression ■  HEART-Primary Graft Dysfunction ■  HEART-Quality of Life/Quality Improvement ■  HEART-Rejection-Antibody Mediated (AMR) ■  HEART-Rejection-Cellular ■  HEART-Telehealth/Remote Monitoring and Interventions ■  HEART-Other (Clinical)
	Advanced Lung Failure and Transplantation
■  LUNG-Basic Science-Immunology, Inflammation ■  LUNG-Basic Science-Infectious Disease (COVID and Non-COVID, Microbiome) ■  LUNG-Basic Science-Models of Organ Preservation, Perfusion and Graft Injury ■  LUNG-Basic Science-Novel Immunosuppression Strategies ■  LUNG-Basic Science-Translational Research ■  LUNG-Basic Science-Xenotransplantation/Regenerative Medicine/Artificial Organs ■  LUNG-Chronic Lung Allograft Dysfunction (CLAD) ■  LUNG-Clinical Ex-Vivo Perfusion and Preservation ■  LUNG-COVID-19 (Clinical) ■  LUNG-Critical Care Medicine/Peri-operative Care ■  LUNG-Diagnostics and Pathology ■  LUNG-Donor Management and Organ Allocation ■  LUNG-Health Equity, Economics, Ethics, Public Policy ■  LUNG-Immunology, Inflammation (Clinical) ■  LUNG-Infectious Diseases ■  LUNG-Multidisciplinary Team Care Delivery (Protocols, Quality Improvement, Service Development) ■  LUNG-Novel Immunosuppression/Desensitization Strategies (Clinical) ■  LUNG-Patient-centered Outcomes (Patient Experience/Symptoms, Bedside Care, Rehabilitation) ■  LUNG-Pediatrics ■  LUNG-Perioperative ECLS/Mechanical Support ■  LUNG-Pharmacology, Therapeutics ■  LUNG-Primary Graft Dysfunction ■  LUNG-Frailty ■  LUNG-Recipient Selection for Transplant and/or Advanced Therapies ■  LUNG-Rejection (Acute) ■  LUNG-Surgical Aspects of Lung Transplantation ■  LUNG-Survival/Prognostication/Risk-Stratification ■  LUNG-Other/Complications (Clinical)
	Mechanical Circulatory Support
■  MCS-Basic Science/Translational Research ■  MCS-Cardiac Complications/Right Heart Failure ■  MCS-Cardiogenic Shock/Temporary Mechanical Support ■  MCS-Devices and Engineering ■  MCS-Hemocompatibility/Stroke/Anticoagulation ■  MCS-Infectious Complications ■  MCS-Myocardial Recovery/Pathologic Aspects ■  MCS-Nursing/Allied Health ■  MCS-Outcomes Research ■  MCS-Patient Management ■  MCS-Patient Selection for Temporary/Durable Support ■  MCS-Pediatrics/Congenital Heart Disease ■  MCS-Peri/Early Postoperative Complications ■  MCS-Pharmacology and Therapeutics ■  MCS-Quality of Life/Psychosocial/Palliative Care ■  MCS-Surgical Techniques ■  MCS-Other
	Pulmonary Vascular Disease
■  PVD-Basic Science/Translational Research ■  PVD-PAH/WHO Group I ■  PVD-PH-LHD/WHO Group II ■  PVD-PH-Lung Disease/WHO Group III ■  PVD-CTEPH (including CTED)/WHO Group IV ■  PVD-Innovations in Pulmonary Hypertension ■  PVD-Nursing/Allied Health ■  PVD-Pediatric Pulmonary Hypertension ■  PVD-Right Heart Failure (including acute or chronic) ■  PVD-RV Physiology and Imaging ■  PVD-Other (Clinical)

You will be asked to select the Primary Practice Area most relevant to your research abstract, as well as any additional practice areas applicable.

• ►  Anesthesiology & Critical Care
• ►  Cardiology
• ►  Cardiothoracic Surgery
• ►  Infectious Diseases
• ►  Nursing and Allied Health
• ►  Pathology
• ►  Pediatrics
• ►  Pharmacy and Pharmacology
• ►  Pulmonology
• ►  Research and Immunology

Each year, the ISHLT offers eligible presenting authors the opportunity to be considered for several scientific abstract awards. Visit the Scientific Abstract Awards page for more information.

The submission site includes a series of questions to determine the presenting author’s eligibility for each scientific abstract award. Eligibility criteria for each award is listed below. If you (as submitting author) are not the presenting author, check with the presenting author on their eligibility for these awards before submission.

ELIGIBILITY CRITERIA
 

	Philip K. Caves Award
►   Candidate must be first author and presenter. ►   Candidate must be a student, resident, fellow, or scientist in training. ►   Candidate must be a current ISHLT member or be working under a current ISHLT member. ►   Candidate cannot have previously won this award.
	Early Career Scientist Award
►   Candidate must be first author and presenter. ►   Candidate must be one of the following: ■  a trainee scientist/medical student who does not hold a medical degree ■  an early career nurse ■  an early career pharmacist ►   Candidate must NOT be a post-graduate clinician or hold a faculty position. ►   This abstract must be submitted into a Basic Science category (specified in the selected abstract category title). ►   Candidate cannot have previously won this award. ►   Current ISHLT membership is NOT required.
	Professional Community Awards for Excellence
►   Candidate must be first author and presenter. ►   Candidate must be a current ISHLT member AND a member of one of the ten ISHLT Professional Communities. ►   Candidate cannot have previously won this award.

During abstract submission, the following questions will be asked:

* Is the presenting author an employee or owner of an ineligible company? (Yes/No)
REMINDER: An ACCME-defined ineligible company is an entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

* Are any co-authors listed on the abstract an employee or owner of an ineligible company? (Yes/No)
If yes, enter the co-author name(s), separated by semicolons, in the space provided.

* Does this abstract involve data from an ISHLT Registry? (Yes/No)
If yes, which Registry? (select ISHLT Thoracic Transplant Registry or IMACS Registry)

* Is this abstract based on work that was funded entirely or in part by an ISHLT grant/award? (Yes/No)
If yes, enter the name of the grant/award in the space provided.

* Is this abstract being funding (in part or in whole) by industry? (Yes/No)
If yes, enter the name of the company in the space provided. If more than one company, enter company names separated by semicolons.

In this step, the abstract body (purpose, methods, results, and conclusions) and any tables or images are entered. Abstract submission content should include:

• ►  Brief statement of Purpose of the study (goal or hypothesis being tested)
• ►  Statement of Methods and procedures used
• ►  Summary of Results, presented in sufficient detail to support the conclusion
• ►  Conclusions

SIZE LIMIT

• ►  2140 characters (spaces are ignored)
• ►  Includes characters in the Abstract Title, Abstract Body, Table(s), and Image(s).
• ►  Includes characters in the default headings Purpose, Methods, Results and Conclusions.
• ►  A Table/Image removes 320 characters from your character limit.
• ►  Author names and institutions are not counted in the character limit.

REMINDERS

• ►  Proofread abstracts carefully to avoid errors before submission.
• ►  You may return to your abstract to make corrections to any portion of the abstract submission, including authors, up until the submission deadline.
• ►  Corrections are not permitted after the submission deadline.

A $25 (USD) processing fee must accompany each abstract. ISHLT accepts payment only in the form of MasterCard, Visa and American Express. Purchase orders, checks, and electronic bank transfers will not be accepted. This fee is non-refundable and used to cover the cost of submission and processing.

A disclosure statement must be collected from the Submitting Author. If the abstract is accepted, a disclosure will be collected from the Presenting Author (if different from the Submitting Author).

If all submission steps are completed, the submission is marked COMPLETE and no further action is required but abstracts can still be edited by the submitter until the deadline.

If one or more submission steps are not completed, the system will indicate which steps must be finished before the submission is marked COMPLETE.